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A pathological signature of Alzheimer’s disease (AD) is the formation of 
neurofibrillary tangles comprising filamentous aggregates of the microtubule 
associated protein tau. Tau self-assembly is accelerated by polyanions including 
heparin, an analog of heparan sulfate.  Tau filaments co-localise with heparan 
sulfate proteoglycans (HSPGs) in vivo and HSPGs may also assist the transcellular 
propagation of tau aggregates. Here, we investigate the role of the sulfate moieties 
of heparin in the aggregation of a recombinant tau fragment tau187, comprising 
residues 255-441 of the C-terminal microtubule-binding domain. The effects that the 
selective removal of the N-, 2-O- and 6-O-sulfate groups from heparin have on the 
kinetics of tau aggregation, aggregate morphology and protein structure and 
dynamics were examined. Aggregation kinetics monitored by thioflavin T (ThT) 
fluorescence revealed that aggregation is considerably slower in the presence of 2-
O-desulfated heparin than with N- or 6-O-desulfated heparin.  Transmission electron 
microscopy revealed that tau filaments induced by 2-O-desulfated heparin were 
more slender than filaments formed in the presence of intact heparin or 6-O-
desulfated heparin.  The 2-O-desulfated heparin-induced filaments had more 
extensive regions of flexibility than the other filaments, according to circular 
dichroism and solid-state NMR spectroscopy.  These results indicate that the 
sulfation pattern of heparin regulates tau aggregation, not purely though electrostatic 
forces but also through conformational perturbations of heparin when the 2-O-sulfate 
is removed.  These findings may have implications for the progression of AD, as the 
sulfation pattern of GAGs is known to change during the ageing process, the main 




The assembly of microtubule-associated protein tau (MAPT, or tau; UniProtKB P10636) 
into filamentous aggregates is a pathological hallmark of neurogenerative diseases 
including Alzheimer’s disease (AD) and Pick’s disease, collectively known as 
tauopathies.1, 2  Tau is a water-soluble, intrinsically disordered protein under normal 
physiological conditions and its function is to assist the assembly and stabilisation of 
microtubules and other neuronal cytoskeletal elements. Six isoforms of tau occur in the 
adult human brain;3 the largest (441-aa) isoform consists of two N-terminal inserts (N1, 
N2) and four repeat units (R1-R4) in the microtubule-binding C-terminal region. The 
shorter isoforms lack one or both of the N1 and N2 units and/or the R2 unit. 
Neurofibrillary tangles of abnormally phosphorylated, aggregation-prone tau occur in the 
brains of patients affected by AD, and these consist predominantly of insoluble paired 
helical filaments (PHF) and straight filaments (SF).4, 5   The filaments consist of an 
ordered -sheet amyloid core flanked by a fuzzy, unstructured coat of around 200 
residues that is invisible to transmission electron microscopy (TEM).6  Recent 
visualisation by electron cryo-microscopy, supported by earlier solid-state NMR studies,7, 
8 have revealed that the nanoscale polymorphism of tau PHF and SF originates from 
disease-specific molecular conformations of tau within the fibres,5, 9 raising the possibility 
that neuropathological strains may propagate in a prion-like mechanism.  The molecular 
processes that lead to the formation and propagation of these strains in vivo are far from 
clear and our understanding has until recently depended upon mechanistic studies in 
vitro.    
Studies of the aggregation mechanisms of intact or truncated tau proteins in 
vitro require the addition of arachidonic acid or polyanionic cofactors such as RNA 
and, most commonly, heparin to initiate aggregation.10, 11 Recent results from tissue-
derived filaments pose the question of whether the heparin-induced tau aggregation 
is pathologically relevant.12, 13 Heparin-induced filaments are heterogeneous,13 
possibly reflecting the heterogeneity and polydispersity of the heparin cofactor, and 
the protein molecular conformation differs somewhat from the structures associated 
with AD or Pick’s.  It is worth noting, however, that there is insufficient information 
about the structural variability of filaments obtained from different AD or Pick’s 
brains, given the limited current data and challenges involved.  Further, heparin is 
closely related to heparan sulfate, which was found early on to accumulate with 
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neurofibrillary tangles in the AD brain14 and, when conjugated to proteoglycans, 
assist the cellular uptake and possible propagation of tau via a prion-like seeding 
mechanism15.   
 
Scheme 1. (A) Sequence of the four microtubule binding repeats (R1-R4) and -
strand regions of the heparin-induced 2N4R tau polymorphs (orange, snake; blue, 
twisted; green, jagged) identified by cryo-EM.   (B) Generic structure of the heparin 
disaccharide unit and list of the desulfated heparin derivatives prepared.  
It has often been assumed that heparin-tau interactions are driven largely by 
non-specific ionic interactions between the protein and the sulfate and carboxylate 
groups of heparin,16 but this notion has been challenged by recent results showing 
that the sulfation pattern of HS influences the cellular internalisation of tau, with the 
6-O-sulfate being critical for this process and for tau binding.17-19 Here, using 
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selectively desulfated heparin molecules, we show that the sulfation pattern of 
heparin also influences the rate of aggregation of a truncated tau construct and 
modulates the mass, nanoscale morphology and atomic structure of the filaments 
formed. All experiments were performed with the tau187 construct20 comprising 
residues 255-441 of the tau N2R4 isoform, spanning repeat units R1-R4 and 
encompassing the amyloid core region from N256 to F378 (Scheme 1A). Porcine 
mucosal low-molecular weight heparin (LMWH; approximately 6 kDa, dp18) and high 
molecular weight heparin (HMWH; approximately 16 kDa, dp24-32) were chemically 
modified to remove the 2-O-sulfate groups and/or the 6-O-sulfate groups and/or replace 
the N-sulfates with acetyl groups, yielding 10 derivatives (Scheme 1B).  The residual 
sulfate levels of the 6-O- and 2-O- desulfated LMW heparin derivatives are 61 % and 
70 %, and, of the HMW heparin derivatives are 50 % and 42 %, of the sulfate levels 
of the respective unmodified heparin, as measured by enzymatic digestion followed 
by high-performance anion exchange chromatography (HPAEC). 
Experimental methods 
Tau expression 
The tau construct comprising residues 255-441 of human 4R tau (cDNA clone 
htau46) with the aggregation impeding N terminus removed, leaving the 2nd and 3rd 
repeat microtubule binding (MTB) units, including the highly amyloidogenic 
sequences VQIINK and VQIVYK, respectively. The protein was expressed and 
purified as previously described.20  
Preparation of desulfated heparin  
Unmodified low molecular weight heparin (LMWH) (approx. dp 18) and high 
molecular weight heparin (approx. 36 dp) were purchased from Iduron (Manchester, 
UK). Modified heparin derivatives were prepared through appropriate combinations 
of solvolytic de-sulfation21, 22, involving the removal of iduronate 2-O-sulfation via 2,3-
epoxide formation and subsequent nucleophilic ring opening23 and N-acetylation, 
followed by purification.  Purification involved, for the 6-de-O-sulfated derivatives, a 
precipitation step in ethanol, followed by dialysis (3.5 kDa cut-off, 2 L x 3), gel 
permeation chromatography (Sephadex G-25), cation exchange (Dowex-50 Na+ 
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form) and then freeze-drying. For the 2-O-de-sulfated derivatives, purification 
involved a dialysis step (3.5 kDa cut-off, 2L x 3) followed by GPC (Sephadex G-25) 
and cation exchange (Dowex-50 Na+ form), prior to freeze-drying. The compounds 
were characterised by 1H and 13C NMR spectroscopy in D2O, essentially as 
described,24 to establish the purity and the extent of modification by reference to 
established chemical shift positions. The extent of modification was measured by 
analysis of the HPAEC (Propac PA-1 column 2 x 250 mm) profiles (monitoring the 
double bond formed by lyase treatment at 232 nm) of complete digestion products 
following bacterial (Flavobacterium heparinium) heparinase digestion (hI, hII and hIII) 
in lyase buffer (50 mM sodium acetate, 2.5 mM calcium acetate) and reference to 
standard disaccharides (Dextra Labs, UK) to provide the proportions of each 
constituent disaccharide to be established and the extent of particular substitutions 
to be calculated with reference to the values obtained for the relevant (LMW or 
HMW) heparin starting material. 
Aggregation kinetics of tau 
The formation of amyloid was measured with the amyloid specific dye Thioflavin T 
(ThT). Tau with heparin (20 and 5 μM respectively), were incubated with Tris (30 
mM), DTT (1 mM) at pH 7.5 in the presence of 20 μM Thioflavin at 37 °C. 
Fluorescence measurements, with excitation at 450 nm and emission at 482 nm, 
were taken from triplicate samples on a Molecular Devices Flexstation 3 Microplate 
Reader (Molecular Devices), every 2 minutes for up to 24 h with shaking for 10 
seconds prior to each read.  
Circular dichroism 
Tau (20 μM) was incubated with Tris (30 mM), DTT (1 mM) at pH 7.5 with heparin 
derivates (5 μM) at 37 °C with agitation. Spectra were acquired hourly during the first 
8 hours, followed by acquisition of a final spectrum after 24 hours. Spectra were 
acquired on a Chirascan Plus CD spectrometer between 180 and 260 nm with a 
band width of 1nm, using a path-length of 0.1 mm. Background signals of buffer, and 
the relevant heparin derivative were removed from the spectra.  Measurements were 
collected from triplicate samples, and the averaged spectra were fitted with the 
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BestSel algorithm between 190-250 nm, and percentage of helical, β-sheet, turn and 
unordered components were calculated..25  
Transmission Electron Microscopy 
Tau and heparin (20 and 5 μM, respectively) were incubated with Tris (30 mM), DTT 
(1 mM) at pH 7.5 at 37 °C for 24 hours. A 10 μL suspension was spotted onto carbon 
coated formar grids. After 5 minutes the excess liquid was removed via blotting. For 
negative staining, 10 μL of 2 % phosphotungstic acid was spotted onto the loaded 
grids, and left for 3 minutes before blotting the excess. Grids were viewed on a Jeol 
JEM-1010 electron microscope and images captured that were representative of the 
entire grid. Fibril widths were measured using ImageJ software and the averages 
from 50 measurements was calculated.    
Solid-state NMR experiments 
Following 24 hours of agitated growth of tau (20 M) at 37 ºC in the presence of the 
heparin derivatives (5 mM) , tau aggregates were pelleted by centrifugation at 50000 
g for 1 h in an ultracentrifuge (Beckman Coulter) and the supernatant was removed.  
The fibrils were sedimented by a second centrifugation step. The pellet was 
separated from the supernatant and packed in its hydrated state by 
ultracentrifugation into a 3.2 mm zirconia MAS rotor without further treatment for 
analysis by SSNMR.  
Two-dimensional 13C-13C SSNMR spectra were recorded at a magnetic field 
of 16.3 Tesla on a Bruker Avance III 700 spectrometer, with a 3.2 mm HXY probe 
operating in double resonance mode. The magic-angle frequency was 13 kHz.  The 
operating temperature was 4 °C. Hartmann-Hahn cross-polarization was achieved 
with a 2 ms contact time and 100 kHz proton decoupling with SPINAL-64 was 
applied during signal acquisition.  Spectra were recorded with either 10 ms, 50 ms or 
200 ms mixing times during which the proton nutation frequency was adjusted to the 
MAS frequency of 14 kHz to meet the dipolar-assisted rotational resonance (DARR) 
condition 26. Typically, 480 increments were acquired in the indirect (t1) dimension 
with 400-600 transients per increment, and the total measurement time varied from 
2-7 days depending on the efficiency of rotor packing. Phase-sensitive detection in 
the indirect dimensions was achieved using the States-TPPI method. Chemical shifts 
are expressed relative to tetramethylsilane.  
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The simulated 13C-13C spectrum (Supporting Information, Figure S1) was 
calculated from chemical shifts predicted from the cryo-EM structure of heparin 
induced 2N4R tau snake filaments,12 using a C program written specifically for this 
purpose.  
Results 
Desulfation of heparin influences tau187 aggregation kinetics 
Incubation of tau187 (20 M) with unmodified LMWH in the presence of the 
amyloid-sensitive dye thioflavin T (ThT) indicates that tau aggregation reaches 
completion within 5 h and the aggregation kinetics follow a sigmoidal trajectory consistent 
with a lag phase, filament growth and maturation, with a half-time t0.5 of 0.5 h (Figure 1A).  
Removal of only the 6-O-sulfates of LMWH, or selective replacement of the N-sulfates 
with COCH3, (Figure 1B) has a measureable effect on the aggregation kinetics, 
increasing t0.5 to 1.4 h in both cases.  A considerably slower rate of aggregation is seen 
in the presence of selectively 2-O-desulfated heparin (t0.5 > 6 h).   Removal of the 6-O-
sulfate groups combined with N-acetylation increases t0.5 to 2.4 h, but aggregation is 
much slower when 2-O-desulfation is combined with either 6-O-desulfation or N-
acetylation (t0.5 = 4.5 h) (Figure 1C). Aggregation kinetics in the presence of HMWH are 
also dependent on the sites of heparin desulfation, with tau187 aggregation again being 
considerably slower in the presence of 2-O-desulfated heparin than with the other 
derivatives (Figure 1D).  In summary, the overall rate of heparin-induced tau187 
aggregation to completion is impeded to a greater extent by removing the 2-O-sulfates of 
heparin than it is by removing the 6-O- or N-sulfates. Although the data for tau187 is 
normalized to the final fluorescence emission that was measured, the curve is clearly 
continuing in an upward trajectory, indicating that aggregation had not reached its 
conclusion even after 12 h, and t0.5 is likely to be considerably longer than 6 h. The 
different effect of the selectively desulfated heparin derivatives argues against the tau-
heparin interaction being mediated only by non-specific charge interactions. Other 




Figure 1.  Aggregation kinetics of tau187 (20 M) in the presence of unmodified 
heparin (5 M) monitored by ThT fluorescence. (A) Unmodified and fully desulfated 
LMWH. (B) LMWH desulfated at a single site per disaccharide unit. (C) LMWH 
desulfated at two sites per disaccharide unit. (D) Unmodified HMWH and HMWH 
desulfated at one site per disaccharide. Means and error bars are shown for triplicate 
measurements.  
Concentration dependence of desulfated heparin-induced tau187 aggregation 
To further investigate the effect of the sulfate groups of heparin on tau187 
aggregation, the kinetics were followed (by ThT) at different concentrations of LMWH or 
the 6-O, N-acetylated and 2-O-desulfated derivatives (Figure 2).  The time to completion 
of aggregation (quantified by t0.5) is sensitive to heparin concentration, as is the ThT 
fluorescence at the end point of aggregation, suggesting that the mass of filaments is 
heparin concentration dependent.  Curves calculated for the apparent rate constants for 
primary nucleation (kn), elongation (k+) and secondary nucleation (k2),27, 28 agree well with 
the experimental data (Figure 2 and Table 1). The aggregation rate in the presence of 
unmodified LMWH remains constant up to 10 M heparin (t0.5 ~ 0.5 h), with the final fibril 
mass scaling approximately with heparin concentration. The end-point ThT fluorescence 
also increases with heparin concentration up to 10 M. This trend has been attributed to 
an increase in the fibrillar mass with increasing heparin concentration, which gives rise to 
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enhanced ThT fluorescence.29 Although it is known that many other environmental 
factors or conformational differences can influence ThT fluorescence, it is likely that here 
the ThT curves do indeed reflect the fibril mass, as the heparin concentration (which is 
not ThT reactive) is the only controlled variable.  At an equimolar (20 M) LMWH and 
tau187 concentration, the aggregation rate decreases markedly (t0.5 = 1.7 h) and no 
further increase in ThT fluorescence (or end-point fibril mass) is observed (Figure 2, top 
left).  The reduced rate can be attributed to a reduction in both the apparent kn and k+ 
values (Table 1). The retarding effect of heparin at higher concentrations is known and 
has been attributed to a screening effect of high heparin concentrations because of 
increased ionic strength.30  It has also been proposed that high heparin concentrations 
promote the formation of dead-end, off-pathway tau-heparin complexes.31  A further 
explanation, which will be explored in the next section, is that higher heparin 
concentrations increase the number of 1:1 tau:heparin complexes that are below the 
critical mass necessary to nucleate filament growth.  
 
Figure 2. Aggregation kinetics of tau187 (20 M) in the presence of LMWH or 
derivatives (desulfated at one site per disaccharide) at four concentrations, 
measured by thioflavin T fluorescence.  Means and standard errors are shown from 
triplicate measurements.  Bold lines are the best fitting curves corresponding to the 




When tau187 is incubated with 6-O-desulfated or N-acetylated LMWH, a 2-3-fold 
overall decrease in the rate of aggregation is seen relative to unmodified LMWH, with t0.5 
being 0.9 - 1.7 h (Figure 2, top right and bottom left; Table 1).   Aggregation again follows 
a sigmoidal profile and the reduced rate appears to originate chiefly from a reduction in kn 
and k+.  Fluorescence at the conclusion of aggregation has a non-linear relationship with 
heparin concentrations up to 20 M heparin.  In the presence of 2-O-desulfated LMWH, 
aggregation is substantially slower at all heparin concentrations, with t0.5 in excess of 4 h 
and the growth curves are consistent with an apparent reduction of kn, k+ and k2 (Figure 
2, bottom right; Table 1) compared to the rate constant values in the presence of the 
other cofactors.  Interestingly, the final aggregate mass decreases by 50 % on increasing 
the 2-O-desulfated LMWH concentration from 10 M to 20 M.  
Heparin 6-O-desulfation, but not 2-O-desulfation, reduces the affinity for 
tau187 
The total residual sulfation levels of the 6-O- and 2-O-desulfated LMWH 
molecules are very similar (as are 6-O- and 2-O-desulfated HMWH) and so the large 
differences in the behaviour of these desulfated heparins cannot be attributed entirely to 
their reduced charge density. Indeed, the ThT data reveal a complex relationship 
between the sulfation patterns and concentration of heparin, tau187 aggregation rates 
and filament mass that cannot be explained fully by the apparent rate constants in Table 
1. These rate constants describe a cofactor-independent aggregation mechanism 

















+=         [2] 
Here, M(t) and P(t) are the filament mass and number, respectively, at time t and 
m(t) is the monomer concentration. The term 𝑘𝑛𝑚(𝑡)
𝑛𝑐 represents the formation of 
primary nuclei from monomers (m) with reaction order nc (typically assigned a value 
of 2). The term 𝑘2 𝑚(𝑡)
𝑛2𝑀(𝑡) describes secondary nucleation in a reaction of order 




Table 1. Summary of the apparent rate constants for tau aggregation in the presence 
of unmodified heparin and desulfated derivatives, obtained from the lines of best fit 
to the data in Figure 2.  The calculations were also based on fixed values for the fibril 
dissociation rate constant (km = 1.0 M-1 s-1) and the reaction orders of primary 
nucleation (nc = 2) and secondary nucleation (n2 = 2).27, 28 The reaction orders do not 
necessarily correspond  to the size of the nuclei, but heparin has been shown to interact 
with two tau molecules forming a dimer that nucleates fibril growth.31   Dashes indicate 
where constants could not be calculated because of poor fits to the experimental data. 
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LMWH 2.5 32  17 10 0.51 (0.10) 
 5.0 35  19 10 0.46 (0.10) 
 10.0 33  18 70 0.45 (0.10) 
 20.0 6  4 1 1.70 (0.13) 
LMW-6OH 2.5 4  7 13 1.47 (0.24) 
 5.0 6  9 12 1.12 (0.14) 
 10.0 9  15 16  0.72 (0.12) 
 20.0 6  11 16 0.95 (0.06) 
LMW-NAc 2.5 6  4 10 1.4 (0.13) 
 5.0 5  6 10 1.4 (0.15) 
 10.0 5  8 11 0.9 (0.10) 
 20.0 3  4 10 1.7 (0.10) 
LWM-2OH 2.5 1  2 1 6.5 (0.25) 
 5 2  2 1 5.5 (0.30) 
 10 2  3 1 4.4 (0.30) 
 20 2  2 0 - 
HWMH 2.5 36  19 10 0.5 (0.03) 
 5 28  15 9 0.5 (0.09) 
 10 6  4 6 2.0 (0.05) 
HMW-6OH 2.5 11 7 1 1.7 (0.09) 
 5 10 7 1 1.6 (0.1) 
HMW-2OH 2.5 - - - > 6 h 




2𝑘+𝑚(𝑡)𝑃(𝑡) represents fibril elongation by the addition of monomers to the 
two growing ends of the fibres. We considered minor modifications to these 
equations that might account for the critical involvement of the heparin cofactor, h, in 
the tau187 nucleation and elongation processes, and which may also explain the 
influence of heparin on both aggregation rate and filament mass (Scheme 2).  The 
trends observed can be rationalised if it is assumed that tau187 monomers and 
heparin molecules rapidly establish an equilibrium  
 
Scheme 2. Basic pathway for heparin-induced tau assembly into filaments. 
state 1:1 complex (mh). Neglecting depletion of monomer and heparin 
concentrations by other interaction pathways at this initial condition, the equilibrium 
concentration of the complex [mh] is, according to the standard relationship, given by 





−++−++=    [3] 
where [m]T and [h]T are the total concentrations of free protein monomer and free 
heparin and Kd is the dissociation constant.  The equilibrium is perturbed as mh 
recruits further monomers to form a nucleating species.  Aggregation of the 4-repeat 
domain tau construct in the presence of heparin has been shown to be nucleation 
dependent, with a single heparin molecule binding tau forming an aggregation-
promoting dimer, which then serves as a building block for further fibril growth.31   We 
therefore assume that the smallest primary nucleating species N consists of two tau 
molecules bound to one heparin molecule, m2h. The rate of formation of primary 
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nuclei N thus depends on collisions between free monomeric protein and the mh 







=         [4] 
where nc = 1.  Equations [3] and [4] thus take into account the role of heparin in the 









+=       [5] 
These equations likely oversimplify the tau-heparin interaction, but serve as a 
working hypothesis until the details of the model are further refined with experimental 
input. The simulated curves share similarities with the experimental data in Figure 2, 
the simulations do not replicate exactly the behaviour of the ThT curves and so 
quantitative analysis using global fitting of equations [4] and [5] to the curves was not 
attempted.  However, qualitative inspection of numerically-simulated curves based 
on these adaptations suggest that t0.5 for aggregation and filament mass are both 
sensitive to heparin concentration and to Kd (Figure 3).  
An equilibrium association constant exceeding 106 M-1 (i.e. Kd < 1 M) for tau 
and heparin has been reported.30  According to Eq. [5], when Kd = 0.1 M, t0.5 for 
filament growth does not change markedly at heparin concentrations up to 10 M, 
and the filament mass increases  with heparin concentration up to 10 M (Figure 3, 
top left panel).  At a heparin concentration of 20 M, a considerable increase in t0.5 is 
predicted and the end-point filament mass decreases significantly.  This apparent 
inhibitory effect at higher heparin concentrations can be rationalised as the high-
affinity heparin-tau interaction removing free monomer from solution, leaving little 
remaining heparin to form nuclei and/or elongate the filaments.  These trends in fibril 
mass and t0.5 are reminiscent of the ThT fluorescence curves for tau187 with LMWH 
and LMW-2OH (Figure 2 and Table 1), although the latter curve is consistent with 
much slower aggregation than represented by the simulation.  Hence, removal of the 
2-O-sulfate group does not appear to reduce the affinity of heparin for tau187 
according to these curves. The slower rate of tau aggregation in the presence of 
LMW-2OH, compared to the rates in the presence of the other heparin derivatives is 
reflected in the lower rate constants kn, k+ and k2 calculated by curve fitting (Figure 2 
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and Table 1), which indicates that 2-O-sulfate group is critical for tau primary and 
secondary nucleation and filament elongation. 
 
Figure 3. Calculated fibril mass at four heparin concentrations, based on the 
proposed model. The value of Kd for the initial tau-heparin complex is the only 
variable in the calculations. Using the terminology of Knowles and colleagues, values 
of the remaining constants are: kn = 5 x 10-4 M-1 s-1, k+ = 8 x 106 M-1 s-1. No fibril 
fragmentation of secondary nucleation (i.e., k2 = 0) was assumed for simplification.   
For progressively weaker tau-heparin interactions, the calculated fibril mass in 
the presence of 20 M heparin increases as Kd increases (Figure 3).  At Kd = 50 M, 
a progressive decrease in t0.5 and increase in fibril mass is predicted as the heparin 
concentration is increased. These trends are reminiscent of the ThT curves for tau in 
the presence of LMW-6OH (Figure 2, top right), and support the previous reports that 
6-O-desulfation of heparin reduces its affinity for tau.19  Similarly, at Kd = 5 M, the 
curves are reminiscent of the ThT profiles for tau in the presence of LMW-NAc, 
although there are also some important differences that indicate that our model is 
incomplete.    
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Heparin 2-O-desulfation, but not 6-O-desulfation, affects the structure and 
morphology of tau187 aggregates 
 We next used circular dichroism (CD) spectroscopy to follow the structural 
transformation accompanying tau187 aggregation in the presence of HMWH, HMW-
6OH and HMW-2OH.  CD has indicated that tau aggregation accompanies a transition 
from an unfolded structure to a partially folded structure with approximately ~36 % -
sheet.32  Here, we obtained spectra from freshly prepared tau187-heparin solutions and 
again after incubation at 37°C for 8 h.   In the absence of heparin, the spectrum changes 
little over 8 h (Figure 4A), with a minimum at 200 nm consistent with the protein 
remaining unfolded, and a secondary structure content of 3.7 (± 0.8) % α-helices, 25 (± 
0.4) % -sheet, 18 (± 0.1) % turns and 54 (± 1.2) % unordered. In the presence of 
unmodified heparin, tau187 undergoes a structural transition over 8 h (Figure 4B, left). 
The spectrum at the end-point of aggregation with intact heparin is consistent with 0.7 (± 
1.3) % α-helices, 46 (± 11) % β-sheet, 14 (± 1.2) % turns and 39 (± 9.3) % unordered 
content, and an isodichroic point at around 208 nm. A similar trend is seen in the CD 
spectra of tau187 in the presence of 6-O-desulfated HMWH (Figure 4B, middle) with an 
increase in β-sheet content to 37 (± 3.6) % and no further change, indicating that 
aggregation has reached completion after 8 h with the structural content being similar to 
aggregates formed with unmodified heparin. By contrast, the spectrum of tau187 in the 
presence of 2-O-desulfated HMWH (Figure 4B, right) changes little over 8 h and is 
consistent with 5.3 (± 0.1) % α-helices, 27 (± 2.5) % β-sheet, 17 (± 0.5) % turns and 51 (± 
1.8) % unordered residues, closely resembling the structure content of monomeric 
tau187 after 8 hours.  Furthermore, there is no clear isodichroic point as seen in the 
spectra of tau with HMWH or LMW-6OH. Hence, the CD spectra concur with ThT 
measurements that the rate of tau187 aggregation is slower in the presence of 2-O-




Figure 4. Secondary structure and morphology of tau187 aggregates. (A) CD 
spectra of tau187 (20 M) at 0 h and 8 h. (B)  CD spectra of tau187 in the 
presence of 5 M HMWH, 6-O-desulfated HMWH or 2-O-desulfated HMWH at 0 h 
and 8 h. The samples were incubated at 37°C without agitation. All CD spectra are 
shown as the average of triplicate repeats. (C) TEM images of aggregates formed 
from tau187 (20 M) after incubating with 5 M of HMWH or the desulfated 
derivatives without agitation for 24 h. Scale bar = 200 nm. (D) Distribution of filament 
widths measured from the TEM images. 
The morphology of aggregates formed after incubation with heparin or each of the 
desulfated analogues was visualised by negative-stain TEM. Four tau morphologies 
formed in the presence of heparin, termed snake, twister, hose and jagged, have been 
observed by cryo-EM.12   Here, in the presence of unmodified HMWH, tau187 forms a 
dense network of fibrillar aggregates and upon closer inspection the filaments display a 
sinusoidal curvature pattern with a mean width of 11.8 (± 5.2) nm (Figure 4, C and D, 
left). The intertwined filaments that are characteristic of PHFs, or their crossover points, 
cannot be discerned here, but the width of the filaments is similar to that typically seen for 
paired filaments (10-25 nm).5, 32-34  Aggregates formed in the presence of 6-O-desulfated 
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heparin display a similar morphology and a mean width of 12.7 (± 4.6) (Figure 4, C and 
D, middle), although their sparse deposition is consistent with a lower yield of filaments.  
Filaments formed in the presence of HMW-2OH (Figure 4C, right) are also sparsely 
distributed and display a sinusoidal curvature pattern.  These filaments are noticeably 
more slender than the filaments formed with unmodified heparin, with mean width of 8.5 
(± 2.6) nm (Figure 4D, right). The width of these filaments is more typical of the single 
filaments that are the minor population of tau aggregates associated with AD.33, 34  To 
summarise, heparin 2-O-desulfation has a much more profound effect on tau 
aggregation rate, filament mass, -sheet content and filament morphology than either 6-
O-desulfation or N-acetylation. 
Tau filaments formed with 2-O-desulfated heparin have a reduced -sheet core 
Finally, we used magic-angle spinning (MAS) solid-state NMR (SSNMR) to compare the 
structure and dynamics of uniformly 13C-labeled tau187 fibrils formed in the presence of 
HWMH and HMW-2OH.  Previous SSNMR analyses of heparin-induced aggregates of 
truncated tau constructs indicated that amino acids 306-324 form the rigid -sheet core 
and adopt two distinct conformations7, 8 consistent with the polymorphism of tau filaments 
visualised by cryo-EM.12 Unlike electron microscopy, the flexible N- and C-terminal 
sequences constituting the “fuzzy” regions may be observed by MAS SSNMR using 
INEPT-based methods that correlate nuclear spins through J-couplings, while the 
ordered core is observed selectively using Hartmann-Hahn cross-polarization combined 
with nuclear dipolar recoupling methods.32, 35    
Here, two-dimensional 13C-13C dipolar correlation NMR spectra were obtained 
from fibrils formed by tau187 (20 μM) in the presence of 5 μM HMWH or HMW-2OH.  
By using a short dipolar mixing time (10 ms), the spectra report on the motionally-
restrained residues forming the core of the fibrils. The more flexible outer residues give 
rise to weaker cross-peaks or are not observed.  The peaks are quite broad, which 
probably reflects the known structural heterogeneity of tau filaments formed in the 
presence of heparin.13  No attempt was made to sequentially assign the spectra owing to 





Figure 5. Solid-state magic-angle spinning 13C NMR spectra of uniformly 13C-labelled 
tau187 aggregates formed in the presence of HMWH or 6-O- or 2-O- desulfated 
HMWH derivatives. (A) Top: region of a 13C-13C dipolar correlation NMR spectrum of 
[U-13C] tau187 aggregates formed in the presence of HMWH. Dipolar interactions 
were reintroduced by 5 ms DARR mixing period.  Bottom: A 1H-13C INEPT spectrum 
of the sample sample (B) The 13C-13C dipolar correlation NMR spectrum and INEPT 
spectrum of tau filaments formed in the presence of HMW-2OH. The MAS frequency 
was 13 kHz in all experiments.   
previously studied by SSNMR. Sequential assignment and structural determination could 
in principle be achieved with a combination of 2D and 3D NMR experiments and 
selective isotope labelling, but this was beyond the scope of the present work.  The 
experimental spectrum of tau filaments formed with HMWH is overlaid with a simulated 
spectrum (Supporting Information, Figure S1) generated from 13C chemical shifts 
predicted from the cryo-EM structure of heparin-induced filaments (Table S1),12 which 
are predominantly -sheet/hairpin folds. Good agreement between the simulated and 
experimental spectra suggests that the observed signals originate from the -sheet core 
of the fibrils.  A striking reduction in cross-peak intensities, particularly for cross-peaks 
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representing longer-range couplings, is seen in the spectrum of the fibrils induced by 
HMW-2OH, as compared to the spectrum of fibrils induced by HMWH (Figure 5, A and 
B, top panels).  The reduction in intensity is consistent with a higher degree of overall 
flexibility within the fibrils induced by HMW-2OH. In contrast to the 13C-13C spectra, 1H-
13C INEPT spectra of the exhibit many more peaks than are seen than in the spectrum of 
HMWH-induced filaments  (Figure 5, A and B, bottom panels), confirming that the HMW-
2OH-induced fibrils contain a greater number of flexible residues than do fibrils induced 
by HMWH.  In the INEPT spectrum of HMW-2OH-induced filaments, much stronger 
signals are observed from methyl bearing side chains, but also in the C region, 
indicating that more residues are flexible in the protein backbone. Taken together, these 
observations are consistent with the HMW-2OH-induced filaments having a smaller -
sheet core, flanked by a greater number of mobile residues, compared to the filaments 
formed in the presence of unmodified heparin. 
 
Discussion 
Heparin is a convenient experimental aid to induce the rapid formation of tau 
filaments/fibrils in vitro for mechanistic and structural investigations.  It is a close 
analog of the GAG heparan sulfate, and heparan sulfate proteoglycans (HSPGs) 
such as agrin are commonly associated with A plaques and NFTs in AD.  The 
sulfation patterns of GAGs are known to change with ageing,36, 37 the principal risk-
factor for AD, and so there is biological incentive to investigate how GAG sulfation 
affects tau aggregation, using heparin as a representative GAG.   
Experimental evidence gained over the last decade suggests that the 
progression of neurodegeneration in AD is driven by the transcellular propagation of 
tau aggregates, which seed protein aggregation in the recipient cells in a prion-like 
manner.38, 39  This process may not necessarily be limited to tau aggregates, as 
monomeric tau can also be internalised and seed the aggregation of endogenous 
tau.40  The mechanism of tau release from neurons into the extracellular space is not 
currently known, but the cellular uptake of tau fibrils can occur via binding to 
HSPGs.15  It is conceivable that HSPGs also promote the fibrillisation of tau 
monomers and oligomers in the extracellular space, just as heparin (and HS) do in 
vitro, in addition to facilitating the cellular uptake of fibrils.    
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Here we report that selectively altering the sulfation pattern of heparin affects 
the kinetics of heparin-induced tau187 aggregation and the mass of filaments 
formed, and can also modify the molecular structure of the filaments.  The rate of 
aggregation is slower in the presence of all the desulfated heparins than in the 
presence of native heparin, which may be attributed in part to the lower negative 
charge of the derivatives.  All the heparins desulfated at a single position have 
approximately the same overall sulfation levels, however, and the differences in the 
behaviour of tau in the presence of 6-O-desulfated, 2-O-desulfated and N-acetylated 
heparins suggest that the derivatives have distinctive chemical properties that 
modulate their interactions with tau.  
We propose a basic mechanism for heparin-induced tau aggregation, which 
goes some way toward explaining the aggregation kinetics in the presence of the 
different heparin derivatives, but significant differences between the experimental 
ThT curves and calculated curves indicate that the model is incomplete. A more 
robust analysis may need to take into account the formation of oligomers, 
polymerization via multiple pathways and complex secondary nucleation processes 
involving protein fibrillar and heparin surfaces.  As it stands, the basic model is 
consistent with the 6-O-desulfated and, to a lesser extent, N-desulfated heparin 
having lower affinity for tau than intact heparin. This interpretation agrees with 
previous work: using a heparin-immobilized chip, surface plasmon resonance was 
used to show that N-desulfation and 2-O-desulfation had no effect on heparin 
binding to a tau construct, whereas 6-O-desulfation severely reduced binding.19 In 
addition, cellular studies have shown that heparin interacts with heparan sulfate 
binding sites in tau and prevents binding to cell-surface HSPGs,15 but removal of the 
6-O-sulfates from heparin abolishes the inhibitory effect  whereas 2-O-desulfated 
heparin remains strongly inhibitory.17 Further studies concur that 6-O-sulfation is 
critical for tau-heparan sulfate interactions and that this modification regulates uptake 
in human cell lines and mouse brain slice culture.18    Interestingly, the 6-OS and NS 
glucosamine sulfates, but not the 2-OS iduronate sulfate, of heparin is required for 
binding to A fibrils,41 suggesting a common function for this moiety in amyloid 
binding. 
The most interesting finding here is that 2-O-desulfation of heparin results in a 
markedly greater reduction of the tau187 aggregation rate than does desulfation at 
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the other two sites, and templates tau assembly into a different filament structure 
and morphology. These differences may be rationalised by considering the effects of 
removing sulfate groups on the conformation of heparin.  In addition to losing a 
charge in the form of a sulfate group, the conformation of heparin derivatives is 
sensitive to the substitution pattern in several ways. The iduronate residue is known 
to be in an equilibrium of 1C4 and 2S0 chair and skew boat forms in heparin (67:33 
1C4:2S0 )42 but, following de-O-sulfation at position-2 of the iduronate residue, this 
equilibrium is disturbed, moving in favour of the 1C4 chair form (85:15)43. In addition, 
removal of 2-O-sulfate groups alters the 1JCH NMR coupling constants (C-1 to H-1 
and C-4 to H-4) around the glycosidic linkages, consistent with additional changes in 
conformation,44, 45 for example, the 1JCH values change at A-1 (C-1 to H-1 of 
glucosamine) from 172 to 176 Hz and at I-1 (C-1 to H-1 of the iduronate residue) 
from 147 to 156 Hz.46 The removal of 6-O-sulfate groups from glucosamine, on the 
other hand, while altering chemical shift values principally adjacent to the site of the 
sulfation as expected,24 has less effect elsewhere in the heparin chain, consistent 
with relatively little perturbation of the overall conformation.47 We propose that the 
unique conformational perturbations resulting from 2-O-desulfation must therefore 
modify the tau-heparin interaction in such a way that the conformation of tau is less 
amenable to self-assembly.  One explanation, which is supported by the NMR data, 
is that the core -sheet region of tau is reduced and the flanking fuzzy coat region 
extends further into the core. Why a different filament structure and morphology 
occurs in the presence of 2-O-desulfated heparin can only be speculated upon at 
this stage.  Alterations in the global and local conformation of heparin after 2-O-
desulfation may reduce or otherwise change the charged surface that interacts with 
tau monomers. A distinct primary nucleating species may be formed that directs 
propagation along a structurally and kinetically altered pathway involving interactions 
between fewer core residues.    
There is ample evidence that heparin sulfates accelerate the aggregation of 
monomeric tau in vitro.48  Further work will be necessary to understand fully the 
nature of the tau species that interact with HSPGs during transcellular propagation, 
and to ascertain whether GAGs play a role in filament formation.  It should be noted, 
that protein aggregates in the Alzheimer’s brain principally contains phosphorylated 
tau (P-tau), rather than normal tau, and as such the higher negative charge density 
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would likely repel polyanionic GAGs.  The interplay between tau, P-tau and GAGs 
must therefore be considered in future investigations. The key message of this work 
is that to understand the role of GAG-protein interactions in the formation of amyloid 
fibrils, it is necessary to look beyond electrostatics and to consider the chemical and 
conformational effects conferred on GAGs by their sulfation patterns.     
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